Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
The Royal Society of Chemistry 3, pp
Renal protection with glucagon-like peptide type 1 receptor agonists In CVOTs of arGLP1 renal outcomes were prespecified as key secondary outcomes in 4 studies done with liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatide,58,59,63,64 or were collected as safety parameters in other studies.60 Overall, the prevalence of CKD stage 3 in these studies was low (2030%) (Table 1)
)
In contrast, certain other GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) have demonstrated cardiovascular benefits in their respective outcomes trials
Brain 5, 14
)
US$ 26.71
US$ 29.38
US$ 28.89
US$ 25.95
